{"id":"adjuvant-androgen-deprivation-therapy","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Hot flashes"},{"rate":"40-70","effect":"Erectile dysfunction"},{"rate":"40-60","effect":"Decreased libido"},{"rate":"20-40","effect":"Fatigue"},{"rate":"10-30","effect":"Gynecomastia"},{"rate":"20-40","effect":"Weight gain"},{"rate":"20-50","effect":"Bone density loss / osteoporosis"},{"rate":"5-15","effect":"Cardiovascular events"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This therapeutic approach uses androgen-deprivation agents (such as GnRH agonists, GnRH antagonists, or antiandrogens) to lower circulating testosterone levels, thereby depriving prostate cancer cells of the hormonal signals required for proliferation. In the adjuvant setting, it is administered following primary treatment (surgery or radiation) to reduce the risk of recurrence and improve overall survival in patients with high-risk localized or locally advanced prostate cancer.","oneSentence":"Adjuvant androgen-deprivation therapy suppresses testosterone production to inhibit the growth of hormone-sensitive prostate cancer cells after primary treatment.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:59:52.066Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of high-risk localized or locally advanced prostate cancer following primary therapy (surgery or radiation)"}]},"trialDetails":[{"nctId":"NCT06235697","phase":"PHASE3","title":"Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2024-04-25","conditions":"Prostate Cancer","enrollment":710},{"nctId":"NCT05931419","phase":"","title":"High-Risk prostatE Cancer radiatiOn Versus surgERy","status":"RECRUITING","sponsor":"Comprehensive Cancer Centre The Netherlands","startDate":"2023-02-16","conditions":"Prostate Cancer, Prostate Adenocarcinoma","enrollment":837},{"nctId":"NCT07426055","phase":"PHASE2, PHASE3","title":"PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer","status":"RECRUITING","sponsor":"Affidea Nu-med Center of Oncological DIagnostics and Therapy","startDate":"2026-03-19","conditions":"Prostate Cancer (Adenocarcinoma), Prostate Brachytherapy, Stereotactic Body Radiation Therapy (SBRT)","enrollment":1200},{"nctId":"NCT07027124","phase":"PHASE2","title":"Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-03-19","conditions":"Prostate Cancer, High-risk Prostate Cancer","enrollment":40},{"nctId":"NCT07483658","phase":"NA","title":"Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.","status":"NOT_YET_RECRUITING","sponsor":"CHU de Quebec-Universite Laval","startDate":"2026-02","conditions":"Reccurent/Metastatic Solid Tumor Disease, Prostate Cancer (Post Prostatectomy), Prostate Cancer","enrollment":434},{"nctId":"NCT06952803","phase":"PHASE3","title":"A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-08-06","conditions":"Prostate Cancer","enrollment":700},{"nctId":"NCT07450599","phase":"PHASE2","title":"A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Bayer","startDate":"2026-04-15","conditions":"High-Risk Localized Prostate Cancer","enrollment":250},{"nctId":"NCT03938649","phase":"PHASE2","title":"SRAM study_Postate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"CCTU","startDate":"2019-05-15","conditions":"Advanced Prostate Cancer","enrollment":120},{"nctId":"NCT04947254","phase":"PHASE2","title":"Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-08-05","conditions":"Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8","enrollment":200},{"nctId":"NCT06724159","phase":"","title":"Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.","status":"RECRUITING","sponsor":"Spanish Oncology Genito-Urinary Group","startDate":"2024-12-13","conditions":"Genitourinary Cancers","enrollment":500},{"nctId":"NCT03070886","phase":"PHASE2, PHASE3","title":"Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery","status":"COMPLETED","sponsor":"NRG Oncology","startDate":"2017-04-05","conditions":"Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7","enrollment":612},{"nctId":"NCT07302451","phase":"PHASE2","title":"REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2025-12-01","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":50},{"nctId":"NCT06348264","phase":"PHASE2","title":"Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2024-10-10","conditions":"Salivary Gland Neoplasm Duct","enrollment":37},{"nctId":"NCT01436968","phase":"PHASE3","title":"Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Candel Therapeutics, Inc.","startDate":"2011-09","conditions":"Prostate Cancer","enrollment":711},{"nctId":"NCT05269550","phase":"NA","title":"PSMA MRI Guided Prostate SBRT (ARGOS)/Comprehensive, Longitudinal Evaluation of Imaging Biomarkers Post Radiotherapy (CLIMBER)","status":"ACTIVE_NOT_RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2022-05-03","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT04523207","phase":"PHASE2","title":"A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-08-19","conditions":"Prostatic Neoplasms","enrollment":108},{"nctId":"NCT06605846","phase":"NA","title":"Otago Exercises on the Risk of Falling in Prostatic Cancer Patients Receiving Androgen Deprivation Therapy","status":"COMPLETED","sponsor":"MTI University","startDate":"2024-09-23","conditions":"Prostate","enrollment":110},{"nctId":"NCT05169112","phase":"PHASE3","title":"Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2023-03-06","conditions":"Prostate Cancer","enrollment":72},{"nctId":"NCT06582446","phase":"PHASE2","title":"Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial)","status":"RECRUITING","sponsor":"German Oncology Center, Cyprus","startDate":"2024-09-16","conditions":"Prostate Cancer","enrollment":30},{"nctId":"NCT06772441","phase":"PHASE2","title":"Artificial Intelligence Driven Personalisation of Radiotherapy and Concomitant Androgen Deprivation Therapy for Prostate Cancer Patients (the HypoPro Trial)","status":"RECRUITING","sponsor":"German Oncology Center, Cyprus","startDate":"2024-11-01","conditions":"Prostate Cancer","enrollment":30},{"nctId":"NCT01255891","phase":"PHASE2","title":"Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma Prostate","status":"COMPLETED","sponsor":"Dr. Tamim Niazi","startDate":"2010-01","conditions":"Adenocarcinoma of the Prostate","enrollment":46},{"nctId":"NCT02799706","phase":"PHASE3","title":"Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2017-09-25","conditions":"Prostate Cancer","enrollment":885},{"nctId":"NCT01542021","phase":"NA","title":"Androgen Deprivation Therapy Prior to Prostatectomy for Patients with Intermediate and High Risk Prostate Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-02-24","conditions":"Prostate Cancer, Prostatic Adenocarcinoma","enrollment":41},{"nctId":"NCT05851547","phase":"PHASE2","title":"Dose Escalation For INtraprostatic LEsions","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2023-11-23","conditions":"Prostatic Neoplasms","enrollment":54},{"nctId":"NCT00541047","phase":"PHASE3","title":"RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery","status":"COMPLETED","sponsor":"University College, London","startDate":"2007-11","conditions":"Gastrointestinal Complications, Prostate Cancer, Sexual Dysfunction","enrollment":4236},{"nctId":"NCT01040624","phase":"NA","title":"Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer","status":"COMPLETED","sponsor":"University of Florida","startDate":"2009-12","conditions":"Prostate Cancer","enrollment":77},{"nctId":"NCT06001619","phase":"PHASE4","title":"Prostate Medication, Metabolism and Gut Microbiota","status":"RECRUITING","sponsor":"Turku University Hospital","startDate":"2022-12-01","conditions":"Prostatic Hyperplasia, Prostate Cancer","enrollment":100},{"nctId":"NCT05778097","phase":"PHASE2","title":"Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2023-04-01","conditions":"Prostate Cancer, Biochemical Recurrence, High Risk","enrollment":103},{"nctId":"NCT03043807","phase":"PHASE2","title":"A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2017-02-22","conditions":"Prostate Cancer","enrollment":26},{"nctId":"NCT00430183","phase":"PHASE3","title":"Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2007-05-08","conditions":"Prostate Cancer","enrollment":788},{"nctId":"NCT00004124","phase":"PHASE3","title":"S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"1999-10-15","conditions":"Prostate Cancer","enrollment":983},{"nctId":"NCT03482089","phase":"NA","title":"Cystoprostatectomy Versus Radiotherapy Combined With ADT for the Treatment of cT4 Prostate Cancer With Bladder Invasion","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2018-06-12","conditions":"Prostate Cancer","enrollment":70},{"nctId":"NCT02064036","phase":"PHASE1","title":"Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2013-06-06","conditions":"Adenocarcinoma of the Prostate","enrollment":17},{"nctId":"NCT02449837","phase":"","title":"Investigation of Circulating Tumor Cells From Cancer Patients Undergoing Radiation Therapy","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2014-05","conditions":"Circulating Tumor Cells","enrollment":162},{"nctId":"NCT02716974","phase":"PHASE2","title":"A Study of Definitive Therapy to Treat Prostate Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-06","conditions":"Prostate Cancer","enrollment":26},{"nctId":"NCT04024475","phase":"","title":"Prostate Cancer Biobank","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2014-11-04","conditions":"Prostatic Neoplasms","enrollment":1323},{"nctId":"NCT02102477","phase":"NA","title":"Surgery Versus Radiotherapy for Locally Advanced Prostate Cancer","status":"RECRUITING","sponsor":"Olof Akre","startDate":"2014-10","conditions":"Prostatic Neoplasms","enrollment":1200},{"nctId":"NCT02175212","phase":"PHASE3","title":"Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer","status":"COMPLETED","sponsor":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","startDate":"2005-11","conditions":"Prostate Adenocarcinoma","enrollment":362},{"nctId":"NCT04086290","phase":"PHASE1, PHASE2","title":"National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer Patients","status":"RECRUITING","sponsor":"Peter Busch Østergren","startDate":"2019-10-10","conditions":"Prostate Cancer Metastatic","enrollment":20},{"nctId":"NCT04093375","phase":"NA","title":"Radical Prostatectomy Versus Radical Radiotherapy for Locally Advanced Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2019-11-01","conditions":"Prostatic Neoplasms","enrollment":600},{"nctId":"NCT01117935","phase":"NA","title":"Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2010-05-30","conditions":"Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Prostate Cancer","enrollment":55},{"nctId":"NCT00528866","phase":"PHASE2","title":"Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2008-04","conditions":"Prostate Cancer","enrollment":80},{"nctId":"NCT03169933","phase":"NA","title":"Combined, Intensified and Modulated Adjuvant Therapy in Prostate Carcinoma","status":"COMPLETED","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2004-01-02","conditions":"Prostate Cancer","enrollment":123},{"nctId":"NCT00193856","phase":"PHASE3","title":"RADAR Trial - Randomised Androgen Deprivation and Radiotherapy","status":"COMPLETED","sponsor":"Trans Tasman Radiation Oncology Group","startDate":"2003-10","conditions":"Prostate Cancer","enrollment":1071},{"nctId":"NCT00589472","phase":"PHASE2","title":"Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-11","conditions":"Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer","enrollment":19},{"nctId":"NCT02135445","phase":"PHASE2","title":"Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2014-06","conditions":"Prostate Cancer","enrollment":103},{"nctId":"NCT00769548","phase":"PHASE3","title":"Radiation Therapy and Hormone Therapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"1995-04","conditions":"Prostate Cancer","enrollment":1322},{"nctId":"NCT00016913","phase":"PHASE2","title":"Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2001-05","conditions":"Prostate Cancer","enrollment":34},{"nctId":"NCT00067015","phase":"PHASE3","title":"Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-05","conditions":"Prostate Cancer","enrollment":3},{"nctId":"NCT00949962","phase":"PHASE3","title":"Post-operative or Early Salvage XRT and ADT for High Risk PCa","status":"TERMINATED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2009-10","conditions":"Prostate Cancer","enrollment":87},{"nctId":"NCT01839994","phase":"PHASE3","title":"Conformal Radiotherapy (CRT) Alone Versus CRT Combined With HDR BT or Stereotactic Body Radiotherapy for Prostate Cancer","status":"UNKNOWN","sponsor":"Maria Sklodowska-Curie National Research Institute of Oncology","startDate":"2013-06","conditions":"Prostate Cancer","enrollment":350},{"nctId":"NCT01398657","phase":"PHASE3","title":"Cryotherapy With or Without Short-term Adjuvant Androgen-Deprivation Therapy in Prostate Cancer","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2011-07","conditions":"Prostate Cancer","enrollment":182},{"nctId":"NCT00684905","phase":"PHASE2","title":"Leuprolide, Bicalutamide, and Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer After External-Beam Radiation Therapy","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2000-04","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT00244920","phase":"PHASE2","title":"Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate Cancer","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2002-01","conditions":"Prostate Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Adjuvant hormone therapy"],"phase":"phase_3","status":"active","brandName":"Adjuvant Androgen-Deprivation Therapy","genericName":"Adjuvant Androgen-Deprivation Therapy","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Adjuvant androgen-deprivation therapy suppresses testosterone production to inhibit the growth of hormone-sensitive prostate cancer cells after primary treatment. Used for Adjuvant treatment of high-risk localized or locally advanced prostate cancer following primary therapy (surgery or radiation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}